<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670653</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0619 - MAGNÓLIA</org_study_id>
    <nct_id>NCT04670653</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Magnólia Nasal Gel in the Treatment of Allergic Rhinitis</brief_title>
  <official_title>National, Multicenter, Randomized, Simple-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Magnólia Nasal Gel in the Treatment of Allergic Rhinitis in Participants With Age Greater Than or Equal to 12 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Magnólia nasal gel in the&#xD;
      treatment of moderate-severe persistent or moderate-severe intermittent allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the reflective total nasal symptom score (rESN) averaged over the entire treatment period.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The participant will answer the nasal symptom score (together with their parents or guardians, for participants with less than 18 years old) every 12 hours, in the participant's diary. The rESN will be the average of the two measurements of the day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>6 to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MAGNÓLIA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two applications in each nostril, once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOMETASONE FUROATE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two applications in each nostril, once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGNÓLIA NASAL GEL</intervention_name>
    <description>Magnólia nasal gel spray</description>
    <arm_group_label>MAGNÓLIA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOMETASONE FUROATE</intervention_name>
    <description>Mometasone furoate nasal spray</description>
    <arm_group_label>MOMETASONE FUROATE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Participants of both sexes, with age greater than or equal to 12 years;&#xD;
&#xD;
          -  Clinical diagnosis of moderate-severe persistent or moderate-severe intermittent&#xD;
             allergic rhinitis, according to the ARIA classification;&#xD;
&#xD;
          -  Present the general status of rhinitis as moderate or severe;&#xD;
&#xD;
          -  Total nasal symptom score greater than or equal to 6 points, with congestion and one&#xD;
             or more of the other symptoms present (itching, runny nose, and sneezing) with a score&#xD;
             greater than or equal to 2 at the screening visit;&#xD;
&#xD;
          -  Present skin sensitization test to at least one aeroallergen;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical and laboratory findings that, in the judgment of the investigator, may&#xD;
             interfere with the safety of research participants;&#xD;
&#xD;
          -  History of alcohol abuse or illicit drug use;&#xD;
&#xD;
          -  Participation in a clinical trial in the year before this study;&#xD;
&#xD;
          -  Pregnancy or risk of pregnancy and lactating patients;&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  Participants who present other clinical forms of rhinitis, such as, but not restricted&#xD;
             to medicated rhinitis, vasomotor and atrophic;&#xD;
&#xD;
          -  Participants dependent on decongestants (nasal or oral) or receiving allergen-specific&#xD;
             immunotherapy;&#xD;
&#xD;
          -  Participants with suggestive signs of upper airways bacterial infection;&#xD;
&#xD;
          -  Participants with grade II or III septum deviation and/or presence of nasal polyps or&#xD;
             other conditions that lead to nasal obstruction;&#xD;
&#xD;
          -  Concomitant chronic or intermittent use of decongestants, antihistamines, or&#xD;
             corticosteroids by inhalation, oral, intramuscular, or intravenous;&#xD;
&#xD;
          -  Concomitant use of potent topical corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

